The FDA seemed to tentatively support the benefits of the investigational monoclonal antibody raxibacumab for treating inhalational anthrax following new animal studies, documents released before a Friday advisory committee meeting showed.
Rabbits that received the antibiotic levofloxacin (Levaquin) in combination with raxibacumab tended to show a greater survival rate (about 17%, P=0.0874) compared with those treated with levofloxacin alone, the FDA said Wednesday.
{iframe}http://www.medpagetoday.com/InfectiousDisease/GeneralInfectiousDisease/35666{/iframe}